Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7536630 | 1.00 | MAPK1 (0.63) | MAPK1ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL3217829 | 0.86 | ALDH1A1 (0.81) | MAPK1ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL1405466 | 0.86 | ALDH1A1 (0.81) | MAPK1ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL3217836 | 0.86 | ALDH1A1 (0.81) | MAPK1ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL3217840 | 0.86 | ALDH1A1 (0.81) | MAPK1ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL1405467 | 0.86 | ALDH1A1 (0.81) | MAPK1ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL17278970 | 0.79 | ALDH1A1 (0.71) | MAPK1ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL11341925 | 0.79 | ALDH1A1 (0.71) | MAPK1ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL11341921 | 0.79 | ALDH1A1 (0.71) | MAPK1ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL20664 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023140597-A1 | PRIMER SET FOR DETECTING CHIKUNGUNYA VIRUS | 한국표준과학연구원 | 2023-07-27 | — | — | WO | disclosed |
| CN-106794264-B | Conjugates comprising neurotensin receptor ligands and uses thereof | 3B制药有限公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-3420102-A1 | METHODS FOR IDENTIFYING AND MODULATING IMMUNE PHENOTYPES | Massachusetts Institute of Technology (US) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017147196-A1 | METHODS FOR IDENTIFYING AND MODULATING IMMUNE PHENOTYPES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-08-31 | — | — | WO | disclosed |
| US-8709725-B2 | Arrays of optical confinements and uses thereof | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8314216-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2012-11-20 | — | — | US | disclosed |
| US-8022172-B2 | Clostridial toxin substrate comprising fluorphore, lanthanide donor complex and botulin toxin recognition sequence for use in detecting clostridial protease activity | ALLERGAN, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7906284-B2 | Arrays of optical confinements and uses thereof | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7846722-B2 | Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity | ALLERGAN, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080220456-A1 | LUMINESCENCE RESONANCE ENERGY TRANSFER (LRET) ASSAYS FOR CLOSTRIDIAL TOXIN ACTIVITY | ALLERGAN, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20020192247-A1 | Thermochromic/photochromic cosmetic compositions | THEISEN LYLE (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020013351-A1 | Compounds possessing neuronal activity | VERTEX PHARMACEUTICALS INCORPORATED | 2002-01-31 | — | — | US | disclosed |
| WO-2001064238-A2 | METHODS AND COMPOSITIONS FOR REGULATING ADIPOCYTES | CURIS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| US-6268384-B1 | DO NOT BIND TO FKBP, AND WHICH DO NOT HAVE MULTI-DRUG RESISTANCE REVERSAL ACTIVITY. | VERTEX PHARMACEUTICALS INCORPORATED | 2001-07-31 | — | — | US | disclosed |
| EP-1100971-A1 | WAVELENGTH-SHIFTING PROBES AND PRIMERS | THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY OF NEW YORK, INC. (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006778-A1 | WAVELENGTH-SHIFTING PROBES AND PRIMERS | THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY OF NEW YORK, INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| US-6013649-A | BOND DISORDERS; AUTOIMMUNE DISEASES; ANTITUMOR AGENTS | MONSANTO COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| EP-0620822-A4 | HYBRIDIZATION OF POLYNUCLEOTIDES CONJUGATED WITH CHROMOPHORES AND FLUOROPHORES TO GENERATE DONOR-TO-DONOR ENERGY TRANSFER SYSTEM. | NANOTRONICS INC (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0620822-A1 | HYBRIDIZATION OF POLYNUCLEOTIDES CONJUGATED WITH CHROMOPHORES AND FLUOROPHORES TO GENERATE DONOR-TO-DONOR ENERGY TRANSFER SYSTEM | NANOTRONICS, INC. (US) | 1994-10-26 | — | — | EP | disclosed |
| WO-1993009128-A1 | HYBRIDIZATION OF POLYNUCLEOTIDES CONJUGATED WITH CHROMOPHORES AND FLUOROPHORES TO GENERATE DONOR-TO-DONOR ENERGY TRANSFER SYSTEM | NANOTRONICS, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013351-A1 | Compounds possessing neuronal activity | BDNF, NGF, GAP43 | MAPK1 1052/4885ALDH1A1 1818/4885TSHR 4059/4885 |
| US-20080220456-A1 | LUMINESCENCE RESONANCE ENERGY TRANSFER (LRET) ASSAYS FOR CLOSTRIDIAL TOXIN ACTIVITY | LCT, LRBA, LTA | MAPK1 4611/4885ALDH1A1 4793/4885TSHR 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.